Enodia Therapeutics
targeting translocon protein secretion
- B2B
About Enodia Therapeutics
Developing AI-driven selective small molecule inhibitors targeting translocon to treat cancer, inflammatory diseases, and viral infections by blocking pathological protein secretion.
Key facts
- Industry
- Biotechnology Research
- Company size
- 11–50 employees
- Headquarters
- Paris, Île-de-France, France
- Founded
- 2025
- Revenue
- $5M – $39.7MTamtam estimate
- SIREN
- 941266710
- Website
- enodiatx.com
- linkedin.com/company/enodiatx
Enodia Therapeutics at a glance
Enodia Therapeutics is a B2B company in the Biotechnology Research industry, headquartered in Paris, Île-de-France, France.
Enodia Therapeutics was founded in 2025.
Enodia Therapeutics has 11–50 employees.
Enodia Therapeutics's revenue is $5M – $39.7M (Tamtam estimate).
Enodia Therapeutics's SIREN number is 941266710.
Frequently asked questions about Enodia Therapeutics
What is Enodia Therapeutics's revenue?
Tamtam estimates Enodia Therapeutics's annual revenue at $5M – $39.7M.
How many employees does Enodia Therapeutics have?
Enodia Therapeutics has 11–50 employees.
Where is Enodia Therapeutics headquartered?
Enodia Therapeutics is headquartered in Paris, Île-de-France, France.
Selling to companies like Enodia Therapeutics?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies